Advancis Buys U.S. Rights to Skin Drug

Advancis Pharmaceutical ( AVNC) continues to move into the anti-infectives space, announcing that it bought the U.S. rights to Keflex, an antibiotic used to treat skin infections, from Eli Lilly ( LLY) for $11 million.

Under the agreement, Advancis will get the exclusive rights to manufacture, market and sell the drug, which is sold generically as cephalexin, and can also submit new drug applications for Keflex. But while cephalexin is the third-most prescribed outpatient antibiotic in the U.S., with sales of $140 million last year, the brand-name Keflex had sales of just $3 million in 2003.

In reaction, shares of Advancis, which have not performed well since hitting the market at $10 on Oct. 17, rose 35 cents, or 5.2%, to $7.08. Shares of Lilly fell 6 cents, or 0.1%, to $69.85.

Advancis will begin recognizing revenue from Keflex effective immediately, but the real draw for the company is the ability to use its pulsatile dosing technology called Pulsys to develop a once-daily version of Keflex. Currently, cephalexin is taken two to four times a day for up to two weeks to eliminate infections.

The company now has Pulsys versions of three of the five most-prescribed antibiotics in the U.S. A month ago, Advancis announced a partnership with Par Pharmaceutical ( PRX) to create a Pulsys version of amoxicillin, after previously announcing a partnership with GlaxoSmithKline ( GSK) to make Pulsys version of amoxicillin/clavulanate.

"The acquisition of Keflex is an illustration of our ongoing mission to develop and acquire antibiotic products that we believe can be improved through our novel pulsatile approach," said Edward Rudnic, chairman, president, and CEO of Advancis. "In addition, we believe the acquisition and subsequent sales of Keflex will enable us to prepare for the eventual commercialization of Pulsys products, including our recently announced lead product under development, Amoxicillin Pulsys."

More from Stocks

Banks Prepare to Up Shareholder Payouts By $30 Billion

Banks Prepare to Up Shareholder Payouts By $30 Billion

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Biotech Firm Sarepta Surges 40% on Positive Test Results

Biotech Firm Sarepta Surges 40% on Positive Test Results